Vontobel Holding
TGTX icon

Vontobel Holding’s TG Therapeutics TGTX Stock Holding History

Vontobel Holding’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,500
Closed -$222K – 1173
2024
Q3 		$222K Buy
+9,500
New +$207K ﹤0.01% 990
2023
Q2 		– Sell
-12,000
Closed -$180K – 1155
2023
Q1 		$180K Sell
12,000
-9,800
-45% -$149K ﹤0.01% 992
2022
Q4 		$258K Buy
+21,800
New +$158K ﹤0.01% 927
2021
Q4 		– Sell
-6,594
Closed -$219K – 1204
2021
Q3 		$219K Buy
6,594
+800
+14% +$24.8K ﹤0.01% 1015
2021
Q2 		$218K Hold
5,794
– – ﹤0.01% 1020
2021
Q1 		$279K Sell
5,794
-3,937
-40% -$189K ﹤0.01% 832
2020
Q4 		$510K Buy
+9,731
New +$329K ﹤0.01% 654

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vontobel Holding's TGTX Position: Q4 2024 in Review

Vontobel Holding sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 9,500 shares — an estimated $222K sold.

Vontobel Holding first reported a position in TGTX in Q4 2020 and held it in 7 quarters. The position peaked at $510K in Q4 2020. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Vontobel Holding reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Vontobel Holding sold 9,500 TG Therapeutics shares in Q4 2024, an estimated $222K.
  • Vontobel Holding first reported a position in TG Therapeutics in Q4 2020 and held it in 7 quarters.
  • Vontobel Holding's TG Therapeutics position peaked at $510K in Q4 2020.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Vontobel Holding's 13F filing for Q4 2024, filed 30 Jan 2025.